Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETH-155008 in R/R B-cell NHL, CLL/SLL and AML
NCT04840784Phase 1Terminated
- Sponsor
- Shengke Pharmaceuticals
- Start
- Jun 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ETH-155008 in B-cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and 1 more, sponsored by Shengke Pharmaceuticals. Primary endpoints: Incidence and severity of adverse events at 4 weeks, Incidence and severity of Serious Adverse Event (SAEs) at 4 weeks and 2 more. Started Jun 2021; status: terminated.
02
Drugs
ETH-155008
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04840784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04840784.